Journal supplement features melanoma nursing
August 16, 2017
Selected abstracts
Collaborative Care in Melanoma: The Essential Role of the Nurse
This article provides perspective from medical oncologists on the importance of this supplement from the Melanoma Nursing Initiative. The authors (a) delineate the challenges inherent in addressing adverse event (AE) management with newer melanoma therapies, particularly in the community setting; (b) illustrate how advanced practice providers with extensive clinical trial experience in melanoma are in a key position to set the agenda and educate colleagues on best practices in AE management; and (c) outline the rationale for the supplement and how it is uniquely tailored to enable community-based oncology nurses and allied health professionals caring for patients with melanoma to reduce the burden of AEs, support adherence, and improve patient outcomes.
Advances in Melanoma: The Rationale for the Melanoma Nursing Initiative
This article provides perspective from medical oncologists on the importance of this supplement from the Melanoma Nursing Initiative. The authors (a) delineate the challenges inherent in addressing adverse event (AE) management with newer melanoma therapies, particularly in the community setting; (b) illustrate how advanced practice providers with extensive clinical trial experience in melanoma are in a key position to set the agenda and educate colleagues on best practices in AE management; and (c) outline the rationale for the supplement and how it is uniquely tailored to enable community-based oncology nurses and allied health professionals caring for patients with melanoma to reduce the burden of AEs, support adherence, and improve patient outcomes.
AT A GLANCE
- Symptom/toxicity management is an issue of critical importance to patients with cancer.
- This initiative provided community-based oncology nurses with tools to reduce the burden of AEs, promote adherence, and support patients through the melanoma treatment journey.
- A collaborative approach to AE management should improve overall outcomes for patients with melanoma.
BRAF/MEK Inhibitor Therapy Consensus Statement from the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events and Potential Drug Interactions
This article provides an overview of this supplement, outlining the needs assessment process the Melanoma Nursing Initiative (MNI) used to determine the immunotherapy and targeted therapy topics for discussion as well as the process for developing the consensus statements. The article provides specific discussion of a unique feature of the MNI, the care step pathways (CSPs) for management of adverse events (AEs) associated with melanoma therapies, and looks to the future in terms of the potential benefits of engaging and enabling oncology nurses to adopt a standardized approach to AE management and adherence promotion for melanoma therapies.
AT A GLANCE
- Nurses have an essential role in managing AEs and promoting adherence in patients receiving newer melanoma therapies.
- This supplement outlines nursing assessment and AE management for melanoma immunotherapies and targeted therapies.
- Early and comprehensive management of AEs by oncology nurses is likely to lead to improved outcomes for patients with melanoma.